We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Predicts Vaccine Immunogenicity

By LabMedica International staff writers
Posted on 09 May 2017
A blood test early after vaccination can predict whether vaccines based on living, modified viruses have had the desired effect within seven days of vaccination.

A new study on systems analysis of immune responses induced by a highly promising vaccine against Ebola, as a couple of possible vaccines have been proposed, and this can inform and accelerate rational development of other new vaccines based on living viruses.

One of the vaccines, which is based on a recombinant vesicular stomatitis virus expressing the glycoprotein of the Zaire strain of the Ebola virus (VSV-ZEBOV), was recently shown to be extremely effective with 100% efficacy against the lethal Ebola virus disease in studies carried out in Guinea and Sierra Leone.

A large team of international scientists collaborating with those at the Geneva University Hospitals and Faculty of Medicine examined plasma samples from 115 healthy volunteers from Geneva who received low-dose (LD) or high-dose (HD) vaccine or placebo. More...
Fifteen plasma chemokines/cytokines were assessed at baseline and on days 1, 2 to 3, and 7 after injection. Significant increases in monocyte-mediated MCP-1/CCL2, MIP-1β/CCL4, IL-6, TNF-α, IL-1Ra, and IL-10 occurred on day one. The study includes 190 healthy individuals from Africa and Europe.

By longitudinal analysis blood samples retrieved from persons who have received the Ebola vaccine, the team could show that a group of cytokines measured in plasma within seven days of the vaccine injection correlates with antibody responses developed six months later. The cytokine signature was also shown to correlate with vaccine reactogenicity observed in some volunteers. A signature explaining 68% of cytokine/chemokine vaccine-response variability was identified. Its score was higher in HD versus LD vaccinees and was associated positively with vaccine viremia and negatively with cytopenia. It was higher in vaccinees with injection-site pain, fever, myalgia, chills, and headache; higher scores reflected increasing severity. In contrast, HD vaccinees that subsequently developed arthritis had lower day one scores than other HD vaccinees. This signature, which reveals monocytes’ critical role in rVSV-ZEBOV immunogenicity and safety across doses and continents, should prove useful in assessments of other vaccines.

Ali M. Harandi, PhD, a co-author of the study said, “The results can also provide information to discover biomarkers for other vaccines based on living vectors. There are ongoing studies which focus on the discovery of molecular biomarkers of the VSV-ZEBOV vaccine in healthy individuals using omics-based technologies in combination with a systems biology approach.” The study was published on April 12, 2017, in the journal Science Translational Medicine.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.